Cepheid announced a new pharma deal with AstraZeneca, Cubist Pharmaceuticals, and GSK intended to promote transformational change in infectious disease therapy.
It will by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics.
Targeting bacterial infections with the right treatment will slow the development of resistance that has led to a crisis in treating infections.
Xpert Carba-R is a rapid test under development for use with rectal swab samples to identify the presence of potentially life threatening bacteria.
Specifically, the consortium is working to extend the number of body sample types from rectal swabs to other body samples such as respiratory samples from patients with pneumonia.
Xpert Carba-R is commercially available outside the US, and is targeted for commercial release in the US in 2015, subject to regulatory approval.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity